Bioxcel Therapeutics Share Price Today
(NASDAQ: BTAI)

Name: Bioxcel Therapeutics Share Price Today (NASDAQ: BTAI) - Bioxcel Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Bioxcel Therapeutics share price is $1.87 & ₹159.81 as on 26 Apr 2025, 2.30 'hrs' IST

$1.87

▲

0.02

(1.08%)

Market is closed - opens 7 PM, 28 Apr 2025

View live Bioxcel Therapeutics share price in Dollar and Rupees. Guide to invest in Bioxcel Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Bioxcel Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Bioxcel Therapeutics share price movements

Today's Low: $1.82
Today's High: $1.90
$1.87
2.62%
Downside
Day's Volatility :4.16%
Upside
1.58%
52 Weeks Low: $1.29
52 Weeks High: $43.52
$1.87
31.02%
Downside
52 Weeks Volatility :97.04%
Upside
95.7%

Bioxcel Therapeutics (BTAI) Returns

Period	Bioxcel Therapeutics	Sector (Health Care)	Index (Russel 2000)
3 Months	-68.37%	-4.8%	0.0%
6 Months	-82.66%	-7.5%	0.0%
1 Year	-95.6%	-1.8%	0.0%
3 Years	-99.12%	2.1%	-9.5%

Bioxcel Therapeutics (BTAI) Key Statistics

in dollars & INR

Previous Close	$1.85
Open	$1.8
Today's High	$1.9
Today's Low	$1.821
Market Capitalization	$10.1M
Today's Volume	$71.1K
52 Week High	$43.52
52 Week Low	$1.29
Revenue TTM	$2.3M
EBITDA	$-64.5M
Earnings Per Share (EPS)	$-25.74
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1766.94%

How to invest in Bioxcel Therapeutics Stock (BTAI) from India?

It is very easy for Indian residents to invest directly in Bioxcel Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bioxcel Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bioxcel Therapeutics or BTAI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bioxcel Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bioxcel Therapeutics shares which would translate to 0.457 fractional shares of Bioxcel Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Bioxcel Therapeutics, in just a few clicks!

Returns in Bioxcel Therapeutics (BTAI) for Indian investors in Rupees

The Bioxcel Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Bioxcel Therapeutics investment value today

Current value as on today

₹7,053

Returns

₹92,947

(-92.95%)

Returns from Bioxcel Therapeutics Stock

₹95,522 (-95.52%)

Dollar Returns

₹2,575 (+2.58%)

Indian investors sentiment towards Bioxcel Therapeutics (BTAI)

-81%

Period: Mar 26, 2025 to Apr 25, 2025. Change in 30 Days versus previous period

Search interest for Bioxcel Therapeutics Stock from India on INDmoney has decreased by -81% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Bioxcel Therapeutics

BlackRock Inc
0.43%
Geode Capital Management, LLC
0.34%
Wells Fargo & Co
0.21%
Renaissance Technologies Corp
0.15%
Millennium Management LLC
0.15%
Bank of America Corp
0.10%

Analyst Recommendation on Bioxcel Therapeutics

Rating

Trend

Buy

69%Buy

30%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Bioxcel Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Bioxcel Therapeutics Stock (BTAI)

What analysts predicted

Upside of 1838.5%

Target:

$36.25

Current:

$1.87

Insights on Bioxcel Therapeutics Stock (Ticker Symbol: BTAI)

Price Movement
In the last 3 months, BTAI stock has moved down by -66.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 214.0K → 366.0K (in $), with an average increase of 41.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -13.65M → -10.85M (in $), with an average increase of 25.7% per quarter
BTAI vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 72.4% return, outperforming this stock by 168.0%
BTAI vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 57.3% return, outperforming this stock by 156.5%
Price to Sales
ForBTAI every $1 of sales, investors are willing to pay $2.1, whereas for Beone Medicines Ltd, the investors are paying $6.8 for every $1 of sales.

Bioxcel Therapeutics Technicals Summary

Sell

Neutral

Buy

Bioxcel Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Bioxcel Therapeutics (BTAI) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bioxcel Therapeutics	-19.91%	-82.66%	-95.6%	-99.12%	-99.64%
Regeneron Pharmaceuticals, Inc.	-5.67%	-35.41%	-32.09%	-10.95%	9.54%
Beone Medicines Ltd	-2.45%	17.93%	66.79%	62.33%	55.25%
Vertex Pharmaceuticals Incorporated	-2.01%	3.38%	23.9%	84.27%	83.41%
Alnylam Pharmaceuticals, Inc.	-10.48%	-15.44%	69.29%	56.6%	70.01%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bioxcel Therapeutics	NA	NA	NA	-23.27	-17.67	-0.72	NA	-30.01
Regeneron Pharmaceuticals, Inc.	15.27	15.27	0.94	39.99	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.35	17.95	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.72	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bioxcel Therapeutics	Buy	$10.1M	-99.64%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$64.0B	9.54%	15.27	31.07%
Beone Medicines Ltd	NA	$28.7B	55.25%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$126.6B	83.41%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.3B	70.01%	NA	-12.37%

About Bioxcel Therapeutics

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Organization	Bioxcel Therapeutics
Employees	37
CEO	Dr. Vimal D. Mehta Ph.D.
Industry	Health Technology

Management People of Bioxcel Therapeutics

Name	Title
Dr. Vimal D. Mehta Ph.D.	Founder, CEO, President, & Director
Mr. Richard I. Steinhart MBA	Senior VP & CFO
Mr. Javier Rodriguez J.D.	Senior VP, Chief Legal Officer & Corporate Secretary
Dr. Frank D. Yocca Ph.D.	Executive VP & Chief Scientific Officer

Important FAQs about investing in BTAI Stock from India :

What is Bioxcel Therapeutics share price today?

Bioxcel Therapeutics share price today stands at $1.87, Open: $1.80 ; Previous Close: $1.85 ; High: $1.90 ; Low: $1.82 ; 52 Week High: $43.52 ; 52 Week Low: $1.29.

The stock opens at $1.80, after a previous close of $1.85. The stock reached a daily high of $1.90 and a low of $1.82, with a 52-week high of $43.52 and a 52-week low of $1.29.

Can Indians buy Bioxcel Therapeutics shares?

Yes, Indians can invest in the Bioxcel Therapeutics (BTAI) from India.

With INDmoney, you can buy Bioxcel Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bioxcel Therapeutics at zero transaction cost.

How can I buy Bioxcel Therapeutics shares from India?

It is very easy to buy Bioxcel Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bioxcel Therapeutics (BTAI) be purchased?

Yes, you can buy fractional shares of Bioxcel Therapeutics with INDmoney app.

What are the documents required to start investing in Bioxcel Therapeutics stocks?

To start investing in Bioxcel Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.